Arthneeti
All Q1 FY27 results →
S

Shalby Ltd

Q1 FY27Healthcare Services

Shalby Q1 FY27: Revenue ₹47 Cr, PAT ₹10.5 Cr

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹157
Market cap₹1.7K Cr
P/E42.0
Updated26 Aug 2026
Read3 min read

What the Q1 FY27 call signalled

3 of 4 strong

RevenueModerate growth
MarginMargins up
CapexCapex planned
FundraiseFundraise planned

The short version

Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Shalby expects improved profitability and operating leverage across its portfolio, aiming for sustained growth in earnings.

From Shalby Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase.
  • India operations grew 98% YoY, showing increasing product demand and improving execution.
  • US business sales remained stable with modest 9% YoY growth; multiple initiatives in progress to boost US sales.
  • MedTech business aims to sustain strong growth momentum with a maintained CAGR of 93%.
  • Hospital segment occupancy improved, with a 9.8% YoY increase in occupied beds and expected EBITDA margin rise to ~20%.
  • Gurgaon unit achieved EBITDA breakeven, with further occupancy growth expected.

2 more points from Shalby Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Shalby Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
- **Mumbai Expansion (Asha Parekh Hospital, 200 beds):** Planned as a greenfield project with cash CAPEX outlay expected around April 2027. Investment benchmarks and funding sources (debt vs internal accruals) will be assessed once finalized. No additional debt infusion anticipated for existing hospitals or MedTech for now. - **MedTech Business:** Continuing selective investments in products and technologies for sustainable long-term growth; recent CAPEX already deployed, including bunker facility and robotics. Minimal CAPEX planned going forward. - **Operational Efficiencies:** Initiatives underway to reduce cash flow requirements by ~₹3 crores per month through operational improvements and vendor partnerships in MedTech. - **Working Capital & Inventory Optimization:** Ongoing focus on inventory optimization and cash conversion cycle improvements with automated tools and stronger follow-ups. Overall, strategic investments are focused on capacity expansion in Mumbai and enhancing MedTech capabilities with a disciplined CAPEX approach.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
1Health X Platform
Rev 1Mar 1
2Chandan Healthca
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Shalby Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Shalby Ltd said on order book & pipeline — free account, 30 seconds.

Shalby Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹287 Cr, net profit ₹18 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Shalby's management said in earlier quarters

Others in Healthcare Services this season

  • Aatmaj Health (Q1 FY27)

    Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again

  • Asarfi Hospital Ltd (Q1 FY27)

    Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q

  • KMC Speciality (Q1 FY27)

    Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…

  • 3B Blackbio (Q1 FY27)

    Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…

Compare:vs Apollo Hospitalsvs Max Healthcarevs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Shalby Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Shalby Ltd Q1 FY27 results?

Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Shalby expects improved profitability and operating leverage across its portfolio, aiming for sustained growth in earnings.

What is Shalby Ltd share price analysis?

Shalby Ltd currently shows a below-average growth signal. The stock trades at a P/E of 42.0 with a market cap of ₹1,652 Cr. Investors should review the full earnings analysis for detailed insights.

Is Shalby Ltd planning capital expenditure?

Mumbai Expansion (Asha Parekh Hospital, 200 beds): Planned as a greenfield project with cash CAPEX outlay expected around April 2027.

Keep Shalby Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.